Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ACE | P12821 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 2/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352260 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL2759204 | 0.89 | SMN1; SMN2 (0.61) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL30782236 | 0.88 | ALOX15 (0.70) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL8710933 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL8710928 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL2167226 | 0.87 | ALOX15 (0.68) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL1755294 | 0.87 | ALOX15 (0.68) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL170878 | 0.87 | KDM4E (0.69) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL170877 | 0.87 | KDM4E (0.69) | SMN1; SMN2ACEALOX15KDM4EMAPT | |
| SCHEMBL23872546 | 0.86 | ACE (0.62) | SMN1; SMN2ACEALOX15KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461289-B2 | Bioresorbable polymers synthesized from monomer analogs of natural metabolites | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-06-11 | — | — | US | claimed |
| US-8415449-B2 | Bioresorbable polymers synthesized from monomer analogs of natural metabolites | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-09 | — | — | US | claimed |
| US-20120302719-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-11-29 | — | — | US | claimed |
| US-20120197001-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-08-02 | — | — | US | claimed |
| US-20110275782-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-11-10 | — | — | US | claimed |
| EP-2334712-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | Rutgers, The State University of New Jersey (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010033640-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-03-25 | — | — | WO | claimed |
| US-20260133115-A1 | MASS CYTOMETRY REAGENTS AND METHODS FOR SIGNAL AMPLIFICATION | STANDARD BIOTOOLS CANADA INC. (CA) | 2026-05-14 | — | — | US | disclosed |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12540893-B2 | Mass cytometry reagents and methods for signal amplification | STANDARD BIOTOOLS CANADA INC. (CA) | 2026-02-03 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4634116-A1 | VANADIUM COMPLEXES WITH NITROGEN AND OXYGEN DONOR ATOMS | Borchers GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| WO-2005029066-A2 | DIAGNOSTIC MARKERS AND PHARMACOLOGICAL TARGETS IN HEART FAILURE AND RELATED REAGENTS AND METHODS OF USE THEREOF | AGILENT TECHNOLOGIES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005021712-A2 | MODIFIED MOLECULAR BEACONS | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005019429-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PHAGOCYTOSIS OR PHAGOCYTE ACTIVITY | POTENTIA PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005014615-A2 | SELF-ASSEMBLING PEPTIDES INCORPORATING MODIFICATIONS AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050014181-A1 | Methods and compositions for the assessment of polymer assembly | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| US-20040241748-A1 | Self-assembling arrays and uses thereof | POINTILLISTE, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004071641-A2 | SELF-ASSEMBLING ARRAYS AND USES THEREOF | POINTILLISTE, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | SMN1; SMN2 1241/4885ACE 191/4885ALOX15 1398/4885 |
| US-20110275782-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | BCAT2, WASF2, THEM6 | SMN1; SMN2 4292/4885ACE 2039/4885ALOX15 1612/4885 |
| US-20120302719-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | BCAT2, WASF2, THEM6 | SMN1; SMN2 4292/4885ACE 2039/4885ALOX15 1612/4885 |
| US-12540893-B2 | Mass cytometry reagents and methods for signal amplification | CD47, HLCS, SRMS | SMN1; SMN2 1755/4885ACE 1542/4885ALOX15 4850/4885 |
| US-20260133115-A1 | MASS CYTOMETRY REAGENTS AND METHODS FOR SIGNAL AMPLIFICATION | SRMS, THOC2, TSPO | SMN1; SMN2 2729/4885ACE 2199/4885ALOX15 2415/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | SMN1; SMN2 3343/4885ACE 809/4885ALOX15 2113/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | SMN1; SMN2 3125/4885ACE 476/4885ALOX15 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.